JETIR.ORG ISSN: 2349-5162 | ESTD Year : 2014 | Monthly Issue
JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR)
An International Scholarly Open Access, Peer-reviewed, Refereed Journal

Pharmacological interventions for retinal disease and vision disorders

[1] Lamkhade Pooja, [2] Langhe Vaishnavi, [3] Waghmare Arati, [4] Ghode Seema, [5] Prof. Gadge Shubham

[1,2,3,4] Students at Samarth Institute of Pharmacy, Belhe
[5] Professor at Samarth Institute of Pharmacy, Belhe
Department of Pharmacology
Samarth Institute of Pharmacy, Belhe, Maharashtra, India

Abstract : The Treating retinal disease to prevent sight loss is an increasingly important challenge. It provides the sharp central vision for needed for reading, driving and seeing fine detail vital tissue affected by Retinal disorders. They can affect your vision, and some can be serious enough to cause blindness .In situ retina can be easily examined. The macula or the peripheral retina can affected by Retinal disease. Retinopathy of Prematurity (ROP) is an preventable neovascular retinal disease with a lifetime Impact on vision and ocular morbidities. Retinal vessel immaturity and oxygen therapy influenced the various factors including retinal growth factor deficiencies, malnutrition. Intermittent hypoxia, inflammation, infection etc. That all factors a Influenced the Retinal vessel Immaturity. Pharmacological intervention has been employed since laser can have limited success with improving vision. This review provides a Information Related the Retinal disease and vision disorders.

IndexTerms **-retinal disease, ocular drug delivery, nanocarriers, biodegradable polymers.**

I. INTRODUCTION

The prevalence of sight-related diseases has received Increased attention .This is mainly due to the increasing life expectancy of the global population. There were around 188 million people who had or suffer to the minor vision impairment and around 216 million People who had moderate-to-severe sight impairment, and also approximately 40 million people who were legally blind. The impressive expansion of the global elderly population poses enormous challenges for human society in current times and also in the near future. The aging of the population is estimated to increase the health-related costs and burden on health systems. The burden of retinal diseases in the elderly has a major impact on society and on the economy .The economic burden of macular diseases, including AMD and diabetic macular edema (DME), on patients, families, healthcare providers, and government systems may be classified as direct (medical and non-medical disease-related expenses) and indirect (informal care and productivity loss) costs. Vision is often considered to be the most important of senses and the one that most people fear losing. Considerable efforts to combat vision loss continue to be made as blinding ocular diseases .It is more prevalent with an increasingly ageing population. All measurements for quality of life, such as disability - adjusted life - years, confirm that visual impairment is a highly ranked burden in all countries. There are some Common conditions that affect the front of the eye include glaucoma, anterior uveitis, Cataracts, and dry eye diseases. Refractive errors include myopia (near-sightedness), hyperopia (farsightedness), astigmatism (distorted vision at all distances), and presbyopia that occurs between age 40–50 years (loss of the ability to focus up close, inability to read letters of the phone ,book etc.

Types of Vision Problems

1)Blurred vision (called refractive errors)
2)Age-related macular degeneration.
3)Glaucoma.
4)Cataract.
5)Diabetic retinopathy.

The Eye has a complicated vital structure with several anatomical and physiology constraints.
Show in below figure:-

II. OVERVIEW OF RETINAL DISEASE AND VISION DISORDERS:-

Retinal diseases are those that affect your retina, or also the back layer of your eye. The Light goes into your eye through your cornea and through the opening at the center of your iris this is called as the pupil. Your retina is the part of your eye that's it responsible for converting light into electrical signals. Then the optic nerve send the signal to your brain and Image is created. Many parts affect the retinal disease that include macula. The leading causes of visual impairment and irreversible blindness are posterior segment - related diseases . which include glaucoma, age - related macular degeneration (AMD), macular oedema

secondary to retinal vein occlusion (RVO), cytomegalovirus (CMV) retinitis, posterior uveitis, diabetic retinopathy (DR) and retinitis pigmentosa (RP) . A major factor is the ageing population. As the a population becomes healthier and people live longer, the incidence of this degenerative optic neuropathy that reaches a clinically detectable threshold will increase. The retinal neovascularization (RNV) can develop in the retina and infants may experience retinal detachment and a permanent loss of vision in severe cases . Although many angiogenesis-related factors are involved in RNV, we will focus on several major factors .



Fig 1 a) Disorders of ocular- vision Disorders b) Anatomy & elation in vision disorders c) Pathological Stages of vision disorders

III. Symptoms of Retinal Disease:-

1.Eye floaters and flashes.
2.Blurred or altered vision.
3.Blind spots in your central or peripheral vision .
4.Distortions in your vision (for example, straight lines appear crooked).
5.sudden loss of vision.
6.Difficulty seeing at night or adjusting when the light changes.

IV. Pharmacological Approaches for Retinal Disease and Vision Disorders:-

The different classes of drug used for various retinal disease:-

1.Antioxidants
2.Anti – inflammatory: NSAIDs
3.Anti-inflammatory:Corticosteroids
4.Anti-VEGF

Table:-

Drug Class	Representatives	Routes of Administration	Main Barrier to Target	Main Disadvantages
1.Antioxidants	Lutein, Zeaxanthin (& derivatives), Vitamins C and E	Systemic—oral	Blood-retinal	Low bioavailability, low intestinal absorption
2.Anti-inflammatory: NSAIDs	Bromfenac, Nepafenac	Topical	Corneal	Low bioavailability
3.Anti-inflammatory:	Metilprednisolone Dexamethasone	Oral or I .v / SC	Blood-retinal Scleral	systemic adverse reactions low bioavailability
4.Anti-VEGF	Bevacizumab, Aflibercept, Brolucizumab, etc.	IVT	Internal limiting membrane	Surgical procedure (invasive)

4. Anti-VEGF: Bevacizumab, Aflibercept, Brolucizumab, etc.Internal limiting membrane Surgical procedure (invasive)

1. Antioxidants:-

The retina has evolved different antioxidants defenses such as vitamin E, ascorbate, catalase, glutathione (GSH), glutathione-peroxidase, and glutathione-transferases .The different pathologies or increasing age may reduce this antioxidant capacity. The hypothetical role of oxidative stress in the development of retinal diseases has given rise to research on the use of antioxidants as preventive and therapeutic agents in retinal therapy. The studies regarding the use of antioxidants in retinal diseases are complex but support antioxidant supplements as therapeutic aids. Example of antioxidants -vitamin E, ascorbate, catalase, glutathione (GSH), glutathione-peroxidase, and glutathione-transferases.



Fig 2 Role of antioxidants in prevention of vision disorders

2. Anti – inflammatory: NSAIDs-

Anti-inflammatory drugs are administered topically (Bromfenac, Nepafenac), via intravitreal (Triamcinolon).Low bioavailability is the main limitation, especially in topical administration, while the systemic administration frequently causes systemic adverse reactions. Nonsteroidal anti-inflammatory drugs (NSAIDs) are used extensively in ophthalmology for pain and photophobia after photorefractive surgery and to reduce inflammation, and cystoid macular edema of cataract surgery. In ophthalmology, topical NSAIDs are used to stabilize pupillary dilation during intraocular surgery and to treat allergic conjunctivitis and postoperative inflammmation, pain and cystoid macular edema (CME).



Fig 3 Mechanism of action in NSAIDS- Anti-inflammatory Action

3. Anti-inflammatory:Corticosteroids-

The Treatment of ocular inflammation with high-dose intravenous corticosteroids result in substantial clinical improvement for most cases within one month. The strategy of treating ocular inflammation with high dose "pulsed" intravenous corticosteroids it follow by ongoing anti-inflammatory therapy as indicated resulted in substantial improvement for the large majority of cases with active ocular inflammation.

4. Anti-VEGF Agent -

Anti-vascular endothelial growth factor (anti-VEGF) therapy currently plays a central role in the treatment of numerous retinal diseases. Vascular endothelial growth factor (VEGF) is now known to play a central role in the vascular changes associated with the leading causes of blindness in developed countries, namely age-related macular degeneration (AMD), diabetic retinopathy and retinal vein occlusions (RVOs). The origins of anti-VEGF therapy are in oncology, resistance in cancers may provide insight into the culprits of anti-VEGF resistance in retinal diseases . This is a fourth class of drug.Commonly used anti-VEGF drugs include Bevacizumab (Avastin™), Ranibizumab (Lucentis™), Aflibercept (Eylea™), and Pegaptanib (Macugen®).



Fig 4 a) Mechanism of corticosteroids Anti- inflammatory Action b) Mechanism of Anti-VEGF Agent

V. EMERGING AND NOVEL THERAPIES :-

Laser photocoagulation is the most common established therapy for ROP. Anti-VEGF drug can be administered as monotherapy or used with laser therapy. Anti-VEGF therapy has similar efficacy to laser therapy. Cryotherapy has not been commonly used to treat ROP since late 1980s because it causes an more inflammation than laser therapy . Some therapies have shown beneficial effects in ROP, other therapies have inconclusive reports in ROP studies .the ROP therapies under investigation, beta-blockers, caffeine, polyunsaturated fatty acids, and vitamin A are found to be effective in preventing ROP pro gression.

a) Cell Therapy-

The stem cell therapies have been investigated in preclinical and clinical studies of various type of ocular diseases such as retinopathy of prematurity, age-related macular degeneration, and diabetic retinopathy .Stem cells, pluripotent cells with self-regenerating potentials, have been investigated in ROP .Implantation of embryonic stem cell-derived RPE was found to improve visual acuity in patients with severe neovascular AMD in a phase I clinical trial . Even though stem cell transplantation sho wed protective and regenerative effects in ocular diseases, adverse effects of intravitreal stem cell injection such as retinal detachm ent and vision loss were reported .this all the information about the cell therapy.

b) Gene Therapy –

Gene therapy using viral vectors is a potential therapeutic strategy to treat ROP Lentiviruses, adenoviruses, or adeno-associated viruses they are generally used as viral vectors to transfer genes the retina. Gene therapy can be an attractive therapeutic option to treat ROP since it can provide long-term pharmacological effects and may not need frequent administration of drugs. Numerous gene therapies are in clinical trials for ocular diseases including age-related macular degeneration, diabetic macular edema, glaucoma, and hereditary ocular diseases These therapies are designed to slow disease progression and hopefully restore visual function. Gene therapies are typically delivered to target retinal cells by subretinal (SR) or intravitreal (IVT) injection. Retinal gene Therapy strategies shown in below figure.



Fig 5 a) cell therapy b) Gene Therapy

The Current technology showing promise in this area includes imaging and functional testing. The challenge for applying neuroprotective treatments to the clinic is determining the proper dosage . many of the strategies discussed here have very good safety profiles (TUDCA, progesterone, low level electrical stimulation, exercise). The exact dosage to achieve optimal efficacy is not known. This is challenging when most testing starts in pre clinical studies in rodent models of retinal disease .The Calculating optimal doses is another area that the success of neuroprotective strategies in human trials . Many studies are performed on the protective effects of exercise on cognitive health. The one major challenge to translation of neuroprotective strategies to the clinic is the need for sensitive tools for retinal screening and monitoring of disease.



Fig 5 Retinal Gene therapy strategies

VI. Challenges in Retinal disorders:-

Retinal drug delivery is a challenging area in the field of ophthalmic drug delivery. In the ideal drug delivery system for the retina and vitreous humor has not yet been found, despite extensive research. Also the Posterior segment eye diseases present a challenge in treatment due to the complex structures in the eye that itb serve as robust static and dynamic barriers, limiting the penetration, residence time, and bioavailability of topical and intraocular medications.The drugs must be biodegradable to minimize toxicity and adverse reactions, as well as small enough to not affect the visual axis. The development of biodegradable nano-based drug delivery systems (DDSs) can be the solution to these challenges.Through the advances in biodegradable materials, combined with a better understanding or knowledge of ocular pharmacology, the nano-based DDSs have rapidly evolved, showing great promise to overcome challenges currently encountered by clinicians. One major challenge in topical eyedrop delivery is the constant removal of the drug from the eye surface by the lacrimal fluid secretion this is also one of the major challenge this retinal disorder.The Conventional ocular drug formulations face challenges such as low bioavailability and quick clearance, leading to the need for frequent high-dose administrations, which can result in reduced patient compliance and increased side effects. This all the challenge which is shown in the retinal disorder.

VII. Conclusion:-

We are in an exciting time with many developments in pharmacology and technology that have the potential to revolutionize our treatments to prevent blindness. Challenges remain, and still much work is needed before actual real-world, day-to-day therapy results will be seen with these revolutionary drug delivery strategies In conclusion, the studies regarding the use of antioxidants in retinal diseases are complex but support antioxidant supplements as therapeutic aids.The topical treatment of retinal degenerative diseases is limited by the difficulty to deliver effective drug concentrations to the posterior eye structures. In the case of drug classes like NSAIDs, the presence of certain molecular and metabolic features for specific representatives makes the topical administration possible .As we look toward the future, several research trends are poised to play a pivotal role in advancing biodegradable nano-based DDSs.the advances in biodegradable materials combined with a better understanding of ocular pharmacology have allowed for the rapid evolution of biodegradable nano-based DDSs,it offering great promise to overcome the current challenges encountered by an ophthalmologist in the treatment of posterior segment diseases. We believe that the near future holds promising advancements of technologies in the ophthalmologic world for the management of posterior segment diseases. This review highlights the importance of biodegradability in the development of effective drug delivery systems for the eye for further advancements in this field .

VIII. References-

[1] Allen RS, Hanif A, Gogniat MA, Prall BC, Aung MH, Prunty MC, Mees L, Sidhu C, Iuvone PM, Pardue MT, 2015a. BDNF Mediates the Protective Effects of Exercise in the Diabetic Rat Retina, ARVO E-abstract 5184.
[2] Anderson BJ, Rapp DN, Baek DH, McCloskey DP, Coburn-Litvak PS, Robinson JK, 2000. Exercise influences spatial learning in the radial arm maze. Physiol. Behav 70, 425–429.
[3] Barone I, Novelli E, Strettoi E, 2014. Long-term preservation of cone photoreceptors and visual acuity in rd10 mutant mice exposed to continuous environmental enrichment. Mol. Vis 20, 1545–1556.
[4] Bodis-Wollner I, 2009. Retinopathy in Parkinson disease. J. Neural. Transm 116, 1493–1501.

[5] Chrysostomou V, Kezic JM, Trounce IA, Crowston JG, 2014. Forced exercise protects the aged optic nerve against intraocular pressure injury. Neurobiol. Aging 35, 1722–1725.
[6] Bajpai AK, Bajpai J, Saini RK, et al. Smart biomaterial devices: polymers in biomedical sciences. CRC Press; 2016.
[7] Ackl P, Resnikoff S, Bourne R. World blindness visual impairment: despite many successes the problem is growing. Community Eye Health. 2017;30:71–73.
[8] Green WR, Key SN., 3rd Senile macular degeneration: a histopathologic study. Trans Am Ophthalmol Soc. 1977;75:180–254.
[9] Hyon SH. Biodegradable poly lactic acid microspheres for drug delivery systems. Yonsei Med J. 2000;41:720–734. Doi: 10.3349/ymj.2000.41.6.720.
[10] Fierson W.M. Screening Examination of Premature Infants for Retinopathy of Prematurity. Pediatrics. 2018;142:e20183061. Doi: 10.1542/peds.2018-3061.
[11] Hellström A., Smith L.E., Dammann O. Retinopathy of prematurity. Lancet. 2013;382:1445–1457. Doi: 10.1016/S0140-6736(13)60178-6.
[12] Hwa V., Fang P., Derr M.A., Fiegerlova E., Rosenfeld R.G. IGF-I in human growth: Lessons from defects in the GH-IGF-I axis. Nestle Nutr. Inst. Workshop Ser. 2013;71:43–55.
[13] Lee A., Shirley M. Ranibizumab: A Review in Retinopathy of Prematurity. Paediatr. Drugs. 2021;23:111–117.
[14] Jay M. On the heredity of retinitis pigmentosa. Br. J. Ophthalmol. 1982;66:405–416. Doi: 10.1136/bjo.66.7.405.
[15] Campochiaro P.A., Mir T.A. The mechanism of cone cell death in Retinitis Pigmentosa. Prog. Retin. Eye Res. 2018;62:24–37.
[16] World Health Organization International Classification of Diseases 11th Revision. [(accessed on 25 December 2020)].
[17] Urtti A. Challenges and Obstacles of Ocular Pharmacokinetics and Drug Delivery. Adv. Drug Deliv. Rev. 2006;58:1131–1135.
[18] Allyn M.M., Luo R.H., Hellwarth E.B., Swindle-Reilly K.E. Considerations for Polymers Used in Ocular Drug Delivery. Front. Med. 2022;8:787644. Doi: 10.3389/fmed.2021.787644.
[19] Ji T., Kohane D.S. Nanoscale Systems for Local Drug Delivery. Nano Today. 2019;28:100765.
[20] Oshitari T. Neurovascular Impairment and Therapeutic Strategies in Diabetic Retinopathy. Int. J. Environ. Res. Public Health. 2021;19:439. Doi: 10.3390/ijerph19010439.
[21] Kim S., Park S.J., Byun S.J., Park K.H., Suh H.S. Incremental economic burden associated with exudative age-related macular degeneration: A population-based study. BMC Health Serv. Res. 2019;19:1–9. Doi: 10.1186/s12913-019-4666-0.
[22] Chawan-Saad J., Wu M., Wu A., Wu L. Corticosteroids for diabetic macular edema. Taiwan J. Ophthalmol. 2019;9:233–242.
[23] Tajika T., Isowaki A., Sakaki H. Ocular distribution of difluprednate ophthalmic emulsion 0.05% in rabbits. J. Ocul. Pharmacol. Ther. 2011;27:43–49. Doi: 10.1089/jop.2010.0093.
[24] Gupta A., Kafetzis K.N., Tagalakis A.D., Yu-Wai-Man C. RNA therapeutics in ophthalmology—Translation to clinical trials. Exp. Eye Res. 2021;205:108482. Doi: 10.1016/j.exer.2021.108482.
[25] Yeh S., Khurana R.N., Shah M., Henry C.R., Wang R.C., Kissner J.M., Ciulla T.A., Noronha G., PEACHTREE Study Investigators Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis: Phase 3 Randomized Trial. Ophthalmology. 2020;127:948–955. Doi: 10.1016/j.ophtha.2020.01.006.
[26] Partridge L., Deelen J., Slagboom P.E. Facing up to the global challenges of ageing. Nature. 2018;561:45–56.
[27] Bourne R.R.A., Steinmetz J.D., Saylan M., Mersha A.M., Weldemariam A.H., Wondmeneh T.G., Sreeramareddy C.T., Pinheiro M., Yaseri M., Yu C., et al. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: The Right to Sight: An analysis for the Global Burden of Disease Study. Lancet Glob. Health. 2021;9:e144–e160.
[28] Tilma K.K., Bek T. Dilatation of Retinal Arterioles Induced by Topical Dorzolamide for One Week Is Impaired in Patients with Type 1 Diabetes and Mild Retinopathy. Ophthalmologica. 2020;243:236–242.
[29] Wroblewski J.J., Hu A.Y. Topical Squalamine 0.2% and Intravitreal Ranibizumab 0.5 mg as Combination Therapy for Macular Edema Due to Branch and Central Retinal Vein Occlusion: An Open-Label, Randomized Study. Ophthalmic Surg. Lasers Imaging Retin. 2016;47:914–923.